PolyMedix Inc. (PYMX.OB) to Showcase its Staph-Fighting Compound to the Gordon Conference on Antimicrobial Peptides in California
According to the Centers for Disease Control and Prevention, Staphylococcus (staph) bacteria are one of the most common causes of skin infections in the United States. Staph is found in high-traffic facilities such as hospitals, gyms and schools. Some types of the bacteria are drug resistant, generating the need for strict sanitary regulations, as well as the need for the development of treatment to combat bacteria resistant to drugs. PolyMedix Inc. (PYMX.OB) focuses on the development of products to treat infectious diseases such as staph, as well as acute cardiovascular disorders. The company today announced it will present information of…